Literature DB >> 30859397

STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells.

Toru Kawakami1, Nodoka Sekiguchi1,2, Jun Kobayashi3,4, Taku Yamane5, Sayaka Nishina1, Hitoshi Sakai1, Yukio Hirabayashi6, Hideyuki Nakazawa1, Fumihiro Ishida7,8,9.   

Abstract

Chronic lymphoproliferative disorder of natural killer (NK) cells (CLPD-NK) is a rare disease with an indolent clinical course, which is characterized by persistent increase in large granular lymphocytes of NK-cell type. A somatic mutation in signal transducer and activator transcription 3 (STAT3) has been reported in patients with CLPD-NK; however, the details of the mutational profiles and their clinical significance remain unclear. We performed mutation analyses of the STAT3, STAT5B, and TNF-alpha-induced protein 3 (TNFAIP3) genes for mononuclear cell-derived DNA in 17 CLPD-NK patients using allele-specific polymerase chain reaction and amplicon sequencing. Mutations in STAT3 and TNFAIP3 were found in 29% (5/17) and 6% (1/17) of cases, respectively. All patients were negative for STAT5B mutations. In all three STAT3-mutation (+) patients studied, STAT3 mutations were restricted to sorted NK cells. STAT3 mutation (+) patients had a lower hemoglobin level (6.6 g/dL vs. 13.9 g/dL, P = 0.0044) and showed a trend toward reduced neutrophil counts (1.22 × 109/L vs. 3.10 × 109/L, P = 0.070) compared with the STAT3 mutation (-) patients. No mutations in these genes were found in patients with neuropathy. These results suggest that heterogeneity of CLPD-NK and STAT3-mutated NK cells may play a significant role in cytopenia in CLPD-NK patients.

Entities:  

Keywords:  CLPD-NK; Cytopenia; STAT3; TNFAIP3

Mesh:

Substances:

Year:  2019        PMID: 30859397     DOI: 10.1007/s12185-019-02625-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

3.  Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.

Authors:  F C M Braun; P Grabarczyk; M Möbs; F K Braun; J Eberle; M Beyer; W Sterry; F Busse; J Schröder; M Delin; G K Przybylski; C A Schmidt
Journal:  Leukemia       Date:  2011-05-31       Impact factor: 11.528

4.  Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Rajala; Samuli Eldfors; Heikki Kuusanmäki; Arjan J van Adrichem; Thomas Olson; Sonja Lagström; Emma I Andersson; Andres Jerez; Michael J Clemente; Yiyi Yan; Dan Zhang; Andy Awwad; Pekka Ellonen; Olli Kallioniemi; Krister Wennerberg; Kimmo Porkka; Jaroslaw P Maciejewski; Thomas P Loughran; Caroline Heckman; Satu Mustjoki
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

5.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

6.  Frequent inactivation of A20 in B-cell lymphomas.

Authors:  Motohiro Kato; Masashi Sanada; Itaru Kato; Yasuharu Sato; Junko Takita; Kengo Takeuchi; Akira Niwa; Yuyan Chen; Kumi Nakazaki; Junko Nomoto; Yoshitaka Asakura; Satsuki Muto; Azusa Tamura; Mitsuru Iio; Yoshiki Akatsuka; Yasuhide Hayashi; Hiraku Mori; Takashi Igarashi; Mineo Kurokawa; Shigeru Chiba; Shigeo Mori; Yuichi Ishikawa; Koji Okamoto; Kensei Tobinai; Hitoshi Nakagama; Tatsutoshi Nakahata; Tadashi Yoshino; Yukio Kobayashi; Seishi Ogawa
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

7.  STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.

Authors:  Andres Jerez; Michael J Clemente; Hideki Makishima; Hanna Koskela; Francis Leblanc; Kwok Peng Ng; Thomas Olson; Bartlomiej Przychodzen; Manuel Afable; Ines Gomez-Segui; Kathryn Guinta; Lisa Durkin; Eric D Hsi; Kathy McGraw; Dan Zhang; Marcin W Wlodarski; Kimmo Porkka; Mikkael A Sekeres; Alan List; Satu Mustjoki; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

8.  STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia.

Authors:  Fumihiro Ishida; Kazuyuki Matsuda; Nodoka Sekiguchi; Hideki Makishima; Chiaki Taira; Kayoko Momose; Sayaka Nishina; Noriko Senoo; Hitoshi Sakai; Toshiro Ito; Yok-Lam Kwong
Journal:  Cancer Sci       Date:  2014-01-22       Impact factor: 6.716

9.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

Authors:  Roland Schmitz; Martin-Leo Hansmann; Verena Bohle; Jose Ignacio Martin-Subero; Sylvia Hartmann; Gunhild Mechtersheimer; Wolfram Klapper; Inga Vater; Maciej Giefing; Stefan Gesk; Jens Stanelle; Reiner Siebert; Ralf Küppers
Journal:  J Exp Med       Date:  2009-04-20       Impact factor: 14.307

10.  Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.

Authors:  Marina Parry; Matthew J J Rose-Zerilli; Jane Gibson; Sarah Ennis; Renata Walewska; Jade Forster; Helen Parker; Zadie Davis; Anne Gardiner; Andrew Collins; David G Oscier; Jonathan C Strefford
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

View more
  7 in total

1.  Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia.

Authors:  HeeJin Cheon; Jeffrey C Xing; Katharine B Moosic; Johnson Ung; Vivian W Chan; David S Chung; Mariella F Toro; Omar Elghawy; John S Wang; Cait E Hamele; Ross C Hardison; Thomas L Olson; Su-Fern Tan; David J Feith; Aakrosh Ratan; Thomas P Loughran
Journal:  Blood       Date:  2022-05-19       Impact factor: 25.476

2.  Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.

Authors:  Cédric Pastoret; Fabienne Desmots; Gaëlle Drillet; Simon Le Gallou; Marie-Laure Boulland; Alexia Thannberger; Anne-Violaine Doncker; Véronique Salaun; Gandhi Laurent Damaj; Richard Veyrat-Masson; Olivier Tournilhac; Aline Moignet; Céline Pangault; Mikaël Roussel; Thierry Fest; Thierry Lamy
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

3.  A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells.

Authors:  Vanessa Rebecca Gasparini; Andrea Binatti; Alessandro Coppe; Antonella Teramo; Cristina Vicenzetto; Giulia Calabretto; Gregorio Barilà; Annica Barizza; Edoardo Giussani; Monica Facco; Satu Mustjoki; Gianpietro Semenzato; Renato Zambello; Stefania Bortoluzzi
Journal:  Blood Cancer J       Date:  2020-04-22       Impact factor: 11.037

4.  Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations.

Authors:  Kristine C Olson; Katharine B Moosic; Marieke K Jones; Paige M K Larkin; Thomas L Olson; Mariella F Toro; Todd E Fox; David J Feith; Thomas P Loughran
Journal:  Cancer Med       Date:  2020-07-25       Impact factor: 4.452

Review 5.  Toward a Better Classification System for NK-LGL Disorders.

Authors:  Gaëlle Drillet; Cédric Pastoret; Aline Moignet; Thierry Lamy; Tony Marchand
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

Review 6.  The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance.

Authors:  Agnieszka Witalisz-Siepracka; Klara Klein; Bernhard Zdársky; Dagmar Stoiber
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

7.  T-cell large granular lymphocytic (LGL) leukemia consists of CD4+/CD8dim and CD4-/CD8+ LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis.

Authors:  Naoya Kuwahara; Taiichi Kodaka; Yuriko Zushi; Miho Sasaki; Takae Goka; Hayato Maruoka; Yumi Aoyama; Hiroko Tsunemine; Taku Yamane; Jun Kobayashi; Toru Kawakami; Fumihiro Ishida; Tomoo Itoh; Takayuki Takahashi
Journal:  J Clin Exp Hematop       Date:  2019
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.